Your browser doesn't support javascript.
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Bhiman, Jinal N; Richardson, Simone I; Lambson, Bronwen E; Kgagudi, Prudence; Mzindle, Nonkululeko; Kaldine, Haajira; Crowther, Carol; Gray, Glenda; Bekker, Linda-Gail; Shinde, Vivek; Bennett, Chijioke; Glenn, Gregory M; Madhi, Shabir A; Moore, Penny L.
  • Bhiman JN; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Richardson SI; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Lambson BE; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Kgagudi P; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Mzindle N; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Kaldine H; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Crowther C; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Gray G; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Bekker LG; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Shinde V; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Bennett C; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Glenn GM; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Madhi SA; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Moore PL; The South African Medical Research Council, Tygerberg, South Africa.
Sci Rep ; 13(1): 1222, 2023 Jan 21.
Article in English | MEDLINE | ID: covidwho-2212023
ABSTRACT
The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples respectively. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT 1,197) and BA.4/BA.5 (GMT 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Sci Rep Year: 2023 Document Type: Article Affiliation country: S41598-023-27698-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Sci Rep Year: 2023 Document Type: Article Affiliation country: S41598-023-27698-x